Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nemolizumab (Primary)
  • Indications Prurigo nodularis
  • Focus Registrational; Therapeutic Use
  • Acronyms OLYMPIA 1
  • Sponsors Galderma; Galderma Research & Development

    • Most Recent Events

    • 03 Mar 2025 According to the Galderma Media Release, data from the study will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 7-11, 2025 in Orlando, Florida.
    • 18 Feb 2025 According to the Galderma Media Release, the company announced that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency and Swissmedic have granted marketing authorization for nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland, respectively. This approval is based on robust results from the phase III ARCADIA and OLYMPIA clinical trial programs.
    • 14 Feb 2025 According to a Galderma media release, based on the results from phase III ARCADIA and OLYMPIA programs the company announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top